- Q2 2024 Medivir AB Earnings Call Transcript5 days agokr2.93Earnings
- Q4 2023 Medivir AB Earnings Call TranscriptFeb 15, 2024kr3.57Earnings
- Medivir AB to Discuss the Updated Data in Advanced Hepatocellular Carcinoma Call TranscriptJan 23, 2024
- Q3 2023 Medivir AB Earnings Call TranscriptOct 27, 2023kr7.35 (+5.00%)Earnings
- Q2 2023 Medivir AB Earnings Call TranscriptAug 18, 2023kr7Earnings
- Q1 2023 Medivir AB Earnings Call TranscriptApr 27, 2023kr7.92Earnings
- Q4 2022 Medivir AB Earnings Call TranscriptFeb 15, 2023kr7.92Earnings
- Medivir AB at Redeye Fight Cancer Day (Virtual) TranscriptJan 19, 2023
- Q3 2022 Medivir AB Earnings Call TranscriptNov 03, 2022kr7.92Earnings
- Q2 2022 Medivir AB Earnings Call TranscriptAug 19, 2022kr8.05Earnings
- Q1 2022 Medivir AB Earnings Call TranscriptApr 28, 2022kr8.05Earnings
- Q4 2021 Medivir AB Earnings Call TranscriptFeb 15, 2022kr8.35Earnings
- Q3 2021 Medivir AB Earnings Call TranscriptNov 03, 2021kr9.99Earnings
- Medivir AB to Discuss Update on the Progress and Plans for the MIV-818 Program Call TranscriptSep 16, 2021
- Q2 2021 Medivir AB Earnings Call TranscriptAug 19, 2021kr10.56 (-5.55%)Earnings
- Q1 2021 Medivir AB Earnings Call TranscriptApr 28, 2021kr7.88Earnings
- Q4 2020 Medivir AB Earnings Call TranscriptFeb 26, 2021kr8.66Earnings
- Medivir AB to Discuss Exclusive Licensing Agreement with IGM Biosciences for Birinapant Call TranscriptJan 12, 2021
- Q3 2020 Medivir AB Earnings Call TranscriptNov 10, 2020kr14.06Earnings
- Q2 2020 Medivir AB Earnings Call TranscriptAug 20, 2020kr16.6Earnings
- Q1 2020 Medivir AB Earnings Call TranscriptMay 05, 2020kr11.44Earnings
- Medivir AB R&D Day TranscriptMar 02, 2020
- Q4 2019 Medivir AB Earnings Call TranscriptFeb 13, 2020kr14.56Earnings
- Q3 2019 Medivir AB Earnings Call TranscriptNov 27, 2019kr21.55Earnings
- Q2 2019 Medivir AB Earnings Call TranscriptAug 28, 2019kr24.68Earnings
- Medivir AB to Discuss the Development of Phase IA Study with MIV-818 Call TranscriptJun 13, 2019
- Q1 2019 Medivir AB Earnings Call TranscriptMay 03, 2019kr19.08Earnings
Q3 2020 Medivir AB Earnings Call Transcript
Ladies and gentlemen, welcome to the Medivir AB Q3 Report 2020. (Operator Instructions) Today, I'm pleased to present Yilmaz Mahshid, CEO; and Magnus Christensen, CFO of Medivir. Please begin.
()-&
Thank you, operator. A warm welcome for everyone to our quarterly update.
Slide 3, please. And as a reminder, you will find our presentation on our homepage, and I do recommend everyone to read the disclaimer on Slide 3. The agenda for today will be a brief overview of the company and then to be rounded off with our Q3 numbers presented by Magnus.
Slide 4, please. As you all know, many of you who have observed Medivir, the company has been around since 1988 and started off as a virology-focused company. Today, the company is focused on oncology and clinical development, and the company is listed on NASDAQ here in Stockholm. Our proprietary asset, MIV-818, is a liver directed nucleotide prodrug, and we are currently in the Phase Ib clinical development.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)